Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Mereo BioPharma Group plcNASDAQ: MREO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $4.74M rose 20.6% year over year, ahead of the -12.8% change in trailing-twelve-month research & development. Sequentially, it rose 13.0% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.
Context
- Research & development amounted to 3553.2% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +20.6% holds above the trailing-twelve-month pace of -12.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.77M USD
- Year-over-year change
- -15.1%
- 4-year CAGR
- -13.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.77M | -15.1% |
| FY2024 | 2024-12-31 | 20.93M | +20.2% |
| FY2023 | 2023-12-31 | 17.42M | -43.4% |
| FY2022 | 2022-12-31 | 30.75M | -3.3% |
| FY2021 | 2021-12-31 | 31.8M | — |
Research & Development vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -12.8% is the 7th highest of 10, against a peer median of +11.3%.
- Research & development amounts to 3625.8% of revenue for MREO, versus a peer median of 1313.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $126.01M USD | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $92.92M USD | +60.8% | +57.0% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M USD | -17.5% | +9.1% | — |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| FY2025 | A$61.41M AUD | +47.8% | +25.1% | 1217.6% | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M USD | +11.3% | +45.0% | — |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $36.32M USD | +88.9% | +13.6% | — | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding MREO) | — | +11.3% | +18.8% | 1313.6% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.21M | 0 | 10M | 0 | 500K |
| Cost of Revenue | 24.17M | (257.44K) | 2.57M | 1.09M | 133K |
| Gross Profit | 25.04M | 257.44K | 7.43M | (1.09M) | 367K |
| Gross Margin | 50.9% | — | 74.3% | — | 73.4% |
| Research & Development | 31.8M | 30.75M | 17.42M | 20.93M | 17.77M |
| Selling, General & Admin | 21.5M | 23.18M | 18.42M | 26.43M | 23.01M |
| Operating Expenses | 53.3M | 53.92M | 35.84M | 47.36M | 38.62M |
| Depreciation & Amortization | 866.47K | 895.5K | 1.06M | 1.09M | 1.15M |
| EBITDA | 25.49M | (39.98M) | (26.06M) | (40.8M) | (40.47M) |
| EBITDA Margin | 51.8% | — | -260.6% | — | -8094.8% |
| Operating Income | (28.26M) | (53.67M) | (28.42M) | (47.36M) | (38.26M) |
| Operating Margin | -57.4% | — | -284.2% | — | -7651.4% |
| Interest Income | 1.38K | 696K | 2.13M | 3.04M | 2.17M |
| Interest Expense | 5.22M | 3.36M | 2.88M | 1.37M | 255K |
| Other Income / Expenses | 47.48M | 9.21M | (1.58M) | 4.11M | (3.62M) |
| Income Before Tax | 19.22M | (44.46M) | (30M) | (43.25M) | (41.88M) |
| Pre-Tax Margin | 39.1% | — | -300.0% | — | -8375.6% |
| Income Tax Expense | 2.05M | (2.34M) | (532K) | 0 | 0 |
| Net Income | 17.17M | (42.12M) | (29.47M) | (43.25M) | (41.88M) |
| Net Margin | 34.9% | — | -294.7% | — | -8375.6% |
| EPS (Basic) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| EPS (Diluted) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| Weighted Avg Shares | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
| Weighted Avg Shares (Diluted) | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.